The New Tumour Biomarker miRNA‐371‐3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Richard Weiten und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Cisplatin, MicroRNAs, Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cisplatin is used to treat a variety of malignancies, including testicular germ cell tumours (TGCTs). Although cisplatin‐based chemotherapy yields high response rates, a subset of patients develop cisplatin resistance, limiting treatment options and worsening prognosis. Therefore, there is a high clinical need for new therapeutic strategies targeting cisplatin‐resistant TGCTs. MicroRNA‐371a‐3p ( miR‐371 ), the new serum biomarker for TGCTs, shows significantly increased expression in cisplatin‐resistant TGCT cell lines compared to sensitive parental cell lines. However, the functional impact of miR‐371 on cisplatin sensitivity has not been investigated yet. To evaluate the impact of miR‐37 1 on cisplatin sensitivity, antagomirs were used to inhibit miR‐371 expression, resulting in a > 98% decrease in miR‐371 expression. Cisplatin sensitivity was significantly increased after miR‐371 inhibition in cisplatin‐resistant and corresponding parental TGCT cell lines, indicating a strongly reduced viability and increased apoptosis after cisplatin treatment in miR‐371 ‐inhibited cells. Our results suggest that miR‐371 may contribute to the development of cisplatin resistance in TGCTs. Interfering with miR‐371 expression can increase the cisplatin sensitivity of tumour cells, which may represent a promising approach to improve future therapeutic outcomes in patients with TGCTs, especially those with cisplatin‐resistant disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.
- Department of Urology Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Köln, Germany.
- Department of Developmental Pathology, Institute of Pathology, University Hospital Bonn, Bonn, Germany.
- Urological Research Laboratory, Translational UroOncology, Department of Urology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
ORCID-Profile: Richard Weiten, Jörg Ellinger, Daniel Nettersheim
Zitieren
APA
Weiten, R., Engler, T., Schorle, H., Ellinger, J., Saponaro, M., Alajati, A., Nettersheim, D., & Syring-Schmandke, I. (2024). The New Tumour Biomarker miRNA‐371‐3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70314
Vancouver
Weiten R, Engler T, Schorle H, Ellinger J, Saponaro M, Alajati A, et al. The New Tumour Biomarker miRNA‐371‐3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70314
BibTeX
@article{Weiten2024,
author = {Weiten, Richard and Engler, Theadora and Schorle, Hubert and Ellinger, Jörg and Saponaro, Miriam and Alajati, Abdullah and Nettersheim, Daniel and Syring-Schmandke, Isabella},
title = {The New Tumour Biomarker miRNA‐371‐3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70314}
}
EUVIMED